Drug Profile
Research programme: serotonin 1A receptor antagonist - Pfizer
Alternative Names: WAY 405; WAY101405Latest Information Update: 20 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Aminopyridines; Piperazines
- Mechanism of Action 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 20 Sep 2011 No development reported - Preclinical for Cognition disorders in USA (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 01 Sep 2009 Preclinical development is ongoing in cognition disorders in the US